Thus, aPLs promote oxidative perturbations and mitochondrial dysfunction that trigger increased expression of prothrombotic factors and generate an inflammatory cascade with increased expression of several cytokines, chemokines, and mediators of endothelial dysfunction. 2, 3 Furthermore, aPLs cross-react with oxidized low-density lipoproteins, thus accelerating their influx into macrophages, and promoting monocyte activation and atherosclerosis development. 4 Current therapeutic options for the treatment of thrombotic APS remain confined to long-term oral anticoagulation with vitamin K antagonists, which have several drawbacks, including an increased risk of bleeding and recurrent thrombosis with subtherapeutic international normalized ratio. Because more insight is gained about the pathophysiology of the disease and the involved receptors and intracellular pathways, targeted treatment modalities have been proposed as possible alternatives to the current treatment options. Thus, in the past few years, several potential new therapeutic approaches to APS have emerged, including combination of antiaggregants, statins, and direct thrombin inhibitors, among others. [5] [6] [7] Several studies have detached the beneficial effects of coenzyme Q 10 (CoQ 10 ) supplementation on cardiovascular disease (CVD). [8] [9] [10] CoQ 10 is a member of the mitochondrial respiratory chain that plays an important role in cellular metabolism, participating as an electron carrier in both mitochondrial and extramitochondrial membranes and protecting membrane and lipoproteins from protein oxidation and lipid peroxidation. CoQ 10 provides membrane-stabilizing properties and acts as an antioxidant with cell-protective effects, including inhibition of low-density lipoprotein oxidation, and thus the progression of atherosclerosis. Furthermore, CoQ 10 decreases the production of proinflammatory cytokines, as well as blood viscosity, demonstrated to be helpful in patients with heart failure and coronary artery disease. 11 We have recently investigated the role of oxidative stress and mitochondrial dysfunction in the prothrombotic status of patients with APS induced by aPLs and the beneficial effects of supplementing cells in vitro with CoQ 10 . 12 This study demonstrated the presence of an oxidative perturbation in APS patient leukocytes, which was directly related to an inflammatory and prothrombotic status, and relied on alterations in mitochondrial dynamics and metabolism, which were prevented and reverted by in vitro treatment with CoQ 10 .
Those results prompted us to evaluate the in vivo effects of ubiquinol supplementation on the expression of parameters related to inflammation and thrombosis in patients with APS through the implementation of a prospective, randomized, double-masked, placebo-controlled study that was supported by Kaneka Corporation (Osaka, Japan). The cellular and molecular mechanisms involved have been further characterized.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Design and study treatment of the trial: Prospective, randomized, double-masked crossover, placebo-controlled study. Thirty-six patients with APS were randomized to receive reduced coenzyme Q 10 (Q red ; 200 mg/d) or placebo for 1 month. Both the Q red and the placebo capsules were specially produced by the same company (Kaneka Corporation) and were identical in weight and external aspects. Treatments were given for 1 month according to a randomized and crossover design (with wash-out periods of 4 weeks) as described in Figure I in Table  II in the online-only Data Supplement). Clinical and laboratory parameters of the patients with APS included in the Q red protocol are displayed in the Table. Routine and disease-specific clinical and laboratory data were recorded in 4 monthly visits.
Results
Thirty-three of the 36 patients completed the intervention, which increased significantly plasma CoQ 10 levels (3.5±0.6 pmol/µL after Q red versus 1.0±0.10 pmol/µL before Q red ; P<0.05; Figure  II in the online-only Data Supplement). Demographics, clinical manifestations, and treatments other than Q red were equally distributed between the 2 randomized groups. After multivariate analysis, no demographics, clinical manifestations, and treatment rather than Q red was statistically proven to act as a confounding variable.
Q red Supplementation Improved Endothelial Activity
Endothelial function improved notably as shown by the amelioration in the highest perfusion value after occlusion was released in ubiquinol-treated patients, expressed as the difference between peak flow and rest flow values or the hyperemic area ( Figure 1A-1C) . Accordingly, significantly reduced plasma levels of vascular cell adhesion molecule 1 were demonstrated in patients with APS after ubiquinol treatment ( Figure 1D ).
To specifically evaluate the effect of Q red on endothelial dysfunction in these patients, we performed in vitro studies where human umbilical vein endothelial cells were treated with serum obtained from healthy donors or patients with APS before and after Q red treatment. Q red improved the endothelial dysfunction induced by serum from patients with APS before Q red supplementation as demonstrated by the downregulation of reactive oxygen species production ( Figure 1E ), adhesion molecules (ie, vascular cell adhesion molecule 1; Figure VB -VE in the online-only Data Supplement), and inflammatory mediators (ie, interleukin 8 and vascular endothelial growth factor; Figure 1F ). In addition, the expression (at both, gene and protein levels) and activity of the prothrombotic receptor tissue factor (TF) were significantly reduced ( Figure 1F ; Figure  IVA -IVC in the online-only Data Supplement). We further observed a fall near to basal levels in the expression of nitric oxide (NO; Figure VA in the online-only Data Supplement) and NO-producing enzymes (ie, inducible NO synthase and endothelial NO synthase) overexpressed by effect of serum from patients with APS before Q red treatment ( Figure 1F ). Concomitantly, a significant reduction in the activity of p38 MAPK (p38 mitogen-activated protein kinase), the key intracellular pathway regulating the expression of such molecules, was observed ( Figure 1G ).
Q red Reduced Oxidative Status and Mitochondrial Dysfunction
Q red supplementation produced a reduction in both the levels of peroxides and the percentage of monocytes with altered mitochondrial membrane potential (ΔΨm), as well as a significant increase in glutathione (Figure 2A-2C) . In neutrophils, a significant inhibition in peroxide production was observed after Q red treatment, along with a trend in the upregulation of glutathione ( Figure III in the online-only Data Supplement).
At plasma level, we also found a significant increase in total plasma antioxidant capacity, along with a reduction in oxidized low-density lipoprotein levels ( Figure 2D and 2E).
Q red Treatment Promoted Significant Changes in Mitochondrial Ultrastructure and Biogenesis
Electron microscopy analyses indicated that ubiquinol treatment promoted an increase in monocytes' mitochondrial size in terms of both area and calculated volume of mitochondrial profiles appearing in cell sections. Interestingly, Q red produced a significant increase of mitochondrial volume density (ie, the fraction of cell volume occupied by mitochondria), and a trend to increased mitochondrial numeric density (ie, the mean number of mitochondrial profiles per cell volume unit) was observed as well ( Figure 3A and 3B).
In line with this observation, genes participating in mitochondrial biogenesis, including sirtuin 1, peroxisome proliferator-activated receptor γ coactivator 1α, peroxisome proliferation-activated receptor α, nuclear respiratory factor 2α, and nuclear respiratory factor 2β, were significantly increased in monocytes from Q red -treated patients with APS ( Figure 3C ).
Q red Supplementation Improved the Prothrombotic and Inflammatory Status of Patients With APS
Q red supplementation significantly improved the atherosclerosis-related gene profile in monocytes from patients with APS, which was profoundly altered in these autoimmune subjects in relation to healthy donors. Thus, 29 atherosclerosis-related genes were found altered in patients with APS, and 23 of them were significantly reversed by effect of Q red , including numerous chemokines, interleukins, adhesion molecules, lipoproteins, metalloproteinases, and growth factors ( Figure 4A and 4B).
Q red treatment also decreased interleukin 6 and interleukin 8 protein expression levels in monocytes ( Figure 4D and 4E) along with TF expression ( Figure 4C ) and activity ( Figure  IVD in the online-only Data Supplement). Several other proinflammatory mediators (previously reported to be significantly increased in monocytes from patients with APS) 12 were found further reduced in these cells by effect of Q red treatment, including vascular endothelial growth factor, macrophage inflammatory protein 1α, interleukin-1β, interleukin 6, and tumor necrosis factor α ( Figure 4F ). No differences among primary patients with APS and patients with APS+systemic lupus erythematosus were noticed. A gene network showing the inter-relationship between all the Q red -modulated genes in patients with APS (performed by using the Ingenuity Pathways Analysis software) is displayed in Figure 4G .
Q red Prevents the Activation of Several Intracellular Kinases Involved in Thrombosis and Inflammation on Monocytes From Patients With APS
Among the 18 intracellular kinases evaluated in the protein array, Q red supplementation markedly reduced the phosphorylation of 7 protein kinases in APS monocytes, including Akt-Ser, Akt-Thr, AMPKa (AMP-activated protein kinase), ERK1/2 (extracellular signal-regulated kinases), p38 MAPK, S6 ribosomal, and STAT3, all of them previously reported to be directly involved in the immune-mediated chronic inflammation and thrombotic status present in these autoimmune patients (Figure VIA-VIC in the online-only Data Supplement).
Q red Supplementation Prevents NETosis in Patients With APS
Given the relevant contribution of neutrophils to the maintenance of the oxidative status in patients with APS and the proven presence of aPL-induced NETosis in those patients, [12] [13] [14] [15] we further evaluated the regulation of their activity by effect of Q red through the analysis of NETosis. Q red supplementation promoted a significant reduction in the percentage of extruded neutrophil extracellular traps (NETs), evaluated by fluorescence microscopy 
Effects of Q red Are Modulated by Underlying Epigenetic Mechanisms, Such as Regulation of MicroRNAs Associated With Atherothrombosis Development
Differential expression of microRNAs in monocytes of patients with APS before and after Q red treatment was determined using Nanostring microRNA arrays and subsequent validation by real-time reverse transcription polymerase chain reaction. Moreover, interaction networks of those microRNAs and the above identified genes related to atherosclerosis and thrombosis were also identified so that the integrated analysis of validated microRNAs and the altered genes identified in the polymerase chain reaction array of atherosclerosis, using the software Ingenuity Pathways Analysis, demonstrated the presence of a complex network on which several Q red -upregulated microRNAs seemed to control simultaneously the expression of various Q red -downregulated genes. Complete interaction networks are shown in Figure VIIIC in the online-only Data Supplement.
Correlation Studies Showed Co-Ordinated Q red Effects on Prothrombotic Mediators and Epigenetic Modulators
Correlation studies demonstrated that the reduced expression of several prothrombotic and inflammatory mediators in monocytes was inversely related to the increase in plasma CoQ 10 levels found after Q red treatment ( Figure 5A-5F) . Moreover, the rises in plasma CoQ 10 levels were also linked to the changes promoted on genes related to mitochondrial biogenesis ( Figure 5G-5J ). Of note, changes operated on genes linked to mitochondrial biogenesis were found further associated with changes promoted on the levels of microRNAs, inflammatory mediators, and oxidative stress markers (Table I in the online-only Data Supplement).
Discussion
The overall results of this clinical trial demonstrated that Q red supplementation significantly reduced the expression of several prothrombotic parameters in patients with APS. In previous studies, [12] [13] [14] we demonstrated that several mediators of autoimmunity, thrombosis, inflammation, and endothelial dysfunction orchestrate the pathophysiology of atherothrombosis in APS and systemic lupus erythematosus. Moreover, a redox-sensitive pathway, in which mitochondrial alterations perform a relevant Monocytes purified from patients with APS before and after Q red treatment were fixed with aldehydes, post-fixed with osmium tetroxide, dehydrated, and embedded in epoxy resin. Thin sections were cut and stained with uranyl acetate and lead citrate for observation with an electron microscope. A, Representative micrographs of cells treated as described. Arrows indicate individual mitochondria and N indicate nucleus of monocyte. B, Planimetric and stereological analysis showing mitochondrial area, mitochondrial volume and circularity, volume density (Vv), and numeric density (nv) of mitochondria after Q red treatment on 10 patients. *Significant differences (at P<0.05) vs patients before treatment. C, Waterfall plot showing the changes in mRNA levels of a set of genes involved in mitochondrial biogenesis. *Significant differences (at P<0.05) vs placebo. NRF indicates nuclear respiratory factor; PGC-1α, PPAR coactivator 1α; PPARα, peroxisome proliferation-activated receptor α; and SIRT1, sirtuin 1.
role, seems to elicit those pathological processes. Thus, specific treatments that prevent that co-ordinated deregulation, without promoting negative side effects, would be desirable.
The clinical benefits of CoQ 10 supplementation in prevention and treatment of CVDs have been observed in numerous clinical trials. [8] [9] [10] More recently, positive effects of CoQ 10 on biomarkers of oxidative stress and cardiac function in hemodialysis patients have been further demonstrated. 16 Besides, a recent trial showed that daily intake of 100 mg CoQ 10 supplements among patients with metabolic syndrome for 8 weeks had beneficial effects on serum insulin levels, HOMA-IR (homeostasis model assessment of insulin resistance), HOMA-B (homeostasis model assessment of insulin resistance-beta), and plasma total plasma antioxidant capacity concentrations. 17 Thus, there is promising evidence of a beneficial effect of CoQ 10 when given alone or in addition to standard therapies on various inflammatory and prothrombotic diseases, including CVD, renal diseases, and metabolic syndrome, but less extensive evidence exists in autoimmune-associated CVD.
In our hands, first, a direct anticoagulant effect of ubiquinol was established, as demonstrated by the significant inhibition, promoted on APS monocytes, of the expression and activity of TF, the main inductor of the coagulation in vivo previously shown to be directly involved in the pathogenesis of thrombotic complications in primary patients with APS. 18 In addition, parallel changes in the expression of several cytokines, chemokines, cell surface receptors, endothelial cell regulators, and markers related to oxidative stress in those patients after Q red treatment were found intimately connected.
CVD prevention by Q red is mainly dependent on their beneficial effects on vascular redox signaling. 19 Accordingly, various landmarks linked to oxidative stress in patients with (C 1, D 1 , and E 1 ) showing individual values are displayed, in parallel with beeswarm plot (C 2 , D 2 , and E 2 ) showing individual changes of all the patients included in the study in protein levels of monocyte tissue factor (TF), interleukin (IL)-8, and interleukin 6. F, Waterfall plots showing the changes ±SD in mRNA levels of a set of genes related to inflammation and thrombosis in monocytes from patients with APS after treatment with Q red /placebo. G, Gene networks showing inter-relationship between differentially expressed genes after Q red treatment, using Ingenuity Pathways Analysis software. Direct interactions appear in the network diagram as a solid line, whereas indirect interactions appear as a dashed line. *Significant differences (at P<0.05) vs placebo.
APS exhibited altered expression and activity in response to in vivo Q red treatment. Mitochondrial studies further demonstrated a higher abundance of low-potential mitochondria in monocytes, with a lower reactive oxygen species production. We also showed that Q red treatment on patients with APS upregulated genes related to mitochondrial biogenesis, a highly regulated process operating through peroxisome proliferator-activated receptor γ coactivator 1α-dependent nuclear respiratory factors. 20, 21 The improvement on inflammatory and oxidative stress profiles, together with an increase of mitochondrial biogenesis, suggests that alterations in APS monocytes phenotype are highly likely a direct effect of Q red although complementary effects of global improvements in serology activity cannot be ruled out. Our results are congruent with the beneficial effects observed in patients with type 2 diabetes mellitus treated with thiazolidinediones or resveratrol and in patients with systemic lupus erythematosus treated with fluvastatin, which stimulate mitochondrial biogenesis and reduce mitochondrial dysfunction. 14, 22, 23 Thus, the stimulation of mitochondrial biogenesis through pharmacological interventions seems as promising in attenuating the clinical prothrombotic status associated with APS.
The effects of Q red on endothelial dysfunction have not been previously explored. Thus, our study shows for the first time a significant improvement of the microvascular function in patients with APS, with a significant increase in the peak flow and the area of reactive hyperemia after temporary occlusion of blood flow. Accordingly, levels of a cell adhesion molecule, such as vascular cell adhesion molecule 1, were found diminished in plasma of patients with APS after treatment with Q red . Elevated levels of this molecule have been shown to be associated with an increased thrombotic risk in APS by both in vitro and in vivo studies, which jointly demonstrated that aPLs promoted key intracellular events that contributed to the thrombotic complications of APS by controlling the endothelial adhesive phenotype. [24] [25] [26] Thus, these results evidence the positive effects of Q red on endothelial dysfunction, which might be considered in the prevention of cardiovascular events. Our results were further supported by in vitro studies, on which treatment of endothelial cells with serum from patients with APS treated with Q red downregulated the expression of peroxides, adhesion molecules, and inflammatory mediators. A significant antithrombotic effect was further demonstrated in endothelial cells through the inhibition of TF expression and activity. Furthermore, Q red reestablished normal levels of both, NO and enzymes related to the NO activity induced by APS patients' serum, driving an improvement on endothelial function. All in all, our study supports the efficacy of Q red in restoring endothelial function and inhibiting the expression of markers related to inflammation, thrombosis, and cell adhesion in patients with APS.
The anti-inflammatory effects of Q red can be at least partially explained by its impact on proinflammatory signal transduction pathways. Thus, after treatment, various intracellular mediators intimately related to inflammation, thrombosis, and mitochondrial dysfunction displayed reduced activity. We and others previously showed that aPLs from patients with APS induce monocyte expression of TF through the simultaneous activation of nuclear factor-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1 (mitogen-activated protein kinase kinase 1)/ERK pathway, thus supporting a prothrombotic role for those transduction pathways. 27 Moreover, p38 MAPK and MEK-1/ERK signaling pathways, along with intracellular mediators such as AKT or STAT3, have been shown to regulate the expression of almost all the inflammatory molecules found deregulated in patients with APS, and even being activated by aPL-induced reactive oxygen species production.
12,28,29 Therefore, their modulation by effect of Q red treatment underlies their role as Figure 5 . Correlation studies showed co-ordinated reduced coenzyme Q 10 (Q red ) effects on atherothrombotic mediators and epigenetic modulators. A-F, Negative correlation between increased plasma coenzyme Q 10 (CoQ 10 ) levels and reduced mRNA expression in monocytes of tissue factor (TF), vascular endothelial growth factor (VEGF), interleukin 1β (IL-1β), interleukin 8 (IL-8), interleukin 6 (IL-6), and chemokine (C-C motif) ligand 3 (CCL3), or macrophage inflammatory protein 1-α (MIP1-α). G-J, Positive correlation between increased plasma CoQ10 levels and increased mRNA expression levels in monocytes of the biogenesis-related genes sirtuin 1 (SIRT1), PPAR coactivator 1α (PGC-1α), peroxisome proliferation-activated receptor γ (PPARγ), and nuclear respiratory factor-β (NRFβ). molecular pathways involved in the control of several prothrombotic mediators in APS.
Previous studies reported that neutrophils from patients with systemic lupus erythematosus are activated, producing increased levels of reactive oxygen species and leading to aberrant NET formation, which induced endothelial dysfunction and vascular damage, thus driving the development of premature atherosclerosis and CVD in these patients. 30, 31 More recently, it has been demonstrated that the release of NETs by neutrophils, induced by aPLs, constitutes a new mechanism of thrombosis in APS. 15 Hence, we evaluated the effects of Q red supplementation on NETs formation as a putative additional pathway for thrombosis prevention. Our study demonstrated, along with the inhibition in the production of peroxides, a direct effect of Q red in inhibiting NETosis, thus suggesting a direct link among both processes. Because reactive oxidants and NET constituents have been shown to co-ordinately injure host tissue, 32 it is important that these pathways be tightly regulated. Thus, our data point at Q red as a beneficial antioxidant compound that further prevents toxic side effects of NETs in inflammation and thrombosis in patients with APS.
MicroRNAs are small noncoding RNAs that play critical roles in the regulation of host genome expression at the posttranscriptional levels, having a relevant role in autoimmunity and CVD. In patients with APS, we previously identified 2 microRNAs as potential modulators of TF expression (ie, microRNA-19b and microRNA-20a). 33 More recently, several microRNAs, deregulated in monocytes from patients with APS , were demonstrated to modulate the prothrombotic status of those autoimmune patients. 34 With these premises, we investigated the modifications promoted by Q red treatment in the profile of monocyte microRNAs and their relationship with the changes operated on the inflammatory and prothrombotic profile of patients with APS. The data obtained in the present study demonstrated, for the first time, the altered expression of several microRNAs by effect of Q red . The functional classification of those microRNAs allowed us to demonstrate that the majority of them have as potential target molecules/proteins/ transcription factors involved in inflammation and thrombotic processes. Therefore, the increased levels of those microRNAs after Q red supplementation might be associated with a reduction in the prothrombotic profile of patients with APS. Accordingly, the integrated analysis of validated microRNAs and the altered genes identified in the polymerase chain reaction array of atherosclerosis demonstrated the presence of a complex network on which several Q red -upregulated microRNAs seem to control simultaneously the expression of various Q red -downregulated genes. Thus, we have identified novel and specific microRNA-mRNA regulatory networks, related to CVD in patients with APS and modified by effect of Q red .
The present study has the advantage of a randomized crossover design, in which all the participants have experienced Q red and placebo treatments, each individual acting as his/her own control and strengthening the fact that the effects observed are because of the influence of Q red . In summary, our results support the short-term impact of Q red supplementation in the reduced expression of several markers related to inflammation and thrombosis in patients with APS. Because of the notable absence of clinically significant side effects and its potential therapeutic benefits, we propose that Q red might act as a safe adjunct to standard therapies in patients with APS.
